Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Clinical trial NCT01024231 · COMPLETED
Trial details
- NCT number
- NCT01024231
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-14
- Primary completion
- 2014-02-04
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.